Search all content on GOV.UK

The review of the safety of isotretinoin has concluded.

• Updated: 31 October 2023

A patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunction to persist after treatment has stopped. Healthcare professionals are...

• Updated: 29 April 2024

The MHRA will introduce a patient alert card to increase awareness among men taking finasteride about potential psychiatric and sexual side effects

• Updated: 29 April 2024

How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.

• Updated: 27 August 2024

Summary of the latest safety advice for medicines and medical device users

• Updated: 8 April 2025

Pfizer Limited is recalling all distributed batches of Oxbryta 500 mg Tablets. Pfizer Limited has informed the MHRA that the product is being withdrawn due to emerging data from clinical trials and registry-based studies.

• Updated: 30 September 2024

These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.

• Updated: 12 March 2025

How schools should setup a Microsoft Windows laptop or tablet before lending the device to a child, family or young person.

• Updated: 23 June 2022

Get help to classify pharmaceutical products used to treat or prevent diseases or ailments (in humans or animals), including comparators used in clinical trials and placebos.

• Updated: 22 July 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine aprocitentan (Jeraygo) to treat hypertension (high blood pressure) in adults whose blood pressure cannot be adequately controlled by at least three other medicines (also known as resistant hypertension).

• Updated: 17 January 2025